Short Interest in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Rises By 601.2%

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,274,209 shares, an increase of 601.2% from the February 12th total of 181,710 shares. Currently, 9.2% of the shares of the company are sold short. Based on an average daily trading volume, of 2,687,153 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 2,687,153 shares, the short-interest ratio is presently 0.5 days. Currently, 9.2% of the shares of the company are sold short.

Kairos Pharma Price Performance

Shares of Kairos Pharma stock traded down $0.03 during trading on Thursday, hitting $0.60. The stock had a trading volume of 134,898 shares, compared to its average volume of 647,804. The business has a fifty day moving average of $0.69 and a two-hundred day moving average of $0.94. Kairos Pharma has a fifty-two week low of $0.40 and a fifty-two week high of $2.11. The firm has a market cap of $12.49 million, a P/E ratio of -1.94 and a beta of 2.28.

Institutional Trading of Kairos Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd lifted its stake in Kairos Pharma by 290.8% during the fourth quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock valued at $34,000 after purchasing an additional 36,086 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Kairos Pharma during the 3rd quarter valued at $27,000. Finally, Two Sigma Investments LP bought a new stake in shares of Kairos Pharma during the 3rd quarter worth $54,000.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Kairos Pharma in a research report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, Kairos Pharma presently has an average rating of “Buy” and a consensus target price of $8.33.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.